

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Vicki S. ELLIOTT et al

Title: CELL ADHESION AND EXTRACELLULAR  
MATRIX PROTEINS

Appl. No.: 10/524,355

Filing Date: 07/12/2005

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Jan 9, 2006

By Michele M. Simkin

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicants  
Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number		10/524,355
				Filing Date		07/12/2005
				First Named Inventor		Vicki S. Elliott
				Group Art Unit		Unassigned
				Examiner Name		Unassigned
Sheet 1 of 22				Attorney Docket Number		071949-9301

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	5,175,383		Leder et al.	December 29, 1992	
	A2	5,270,163		Gold et al.	December 14, 1993	
	A3	5,474,796		Brennan	December 12, 1995	
	A4	5,605,662		Heller et al.	February 25, 1997	
	A5	5,686,242		Bruice et al.	November 11, 1997	
	A6	5,707,618		Armentano et al.	January 13, 1998	
	A7	5,767,337		Roses et al.	June 16, 1998	
	A8	5,804,413		DeLuca	September 8, 1998	
	A9	5,807,522		Brown et al.	September 15, 1998	
	A10	5,837,458		Minshull et al.	November 17, 1998	
	A11	5,840,484		Seilhamer et al.	November 24, 1998	
	A12	5,910,434		Rigg et al.	June 8, 1999	
	A13	5,914,236		Monsma, Jr. et al.	June 22, 1999	
	A14	5,932,435		Atkins et al.	August 3, 1999	
	A15	5,997,848		Patton et al.	December 7, 1999	
	A16	6,022,691		Bruice et al.	February 8, 2000	
	A17	6,057,101		Nandabalan et al.	May 2, 2000	
	A18	6,372,724		Pelleg et al.	April 16, 2002	

FOREIGN PATENT DOCUMENTS								
Exam iner Initial s*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		B1	WO95/25116		CALIFORNIA INST OF TECHN (US)	1995-09-21		
		B2	WO95/35505		UNIV LELAND STANFORD JUNIOR (US)	1995-12-28		
		B3	WO84/03564		COMMW SERUM LAB COMMISSION (AU)	1984-09-13		

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/524,355
				Filing Date	07/12/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C1	Aberle, H. et al., "Cadherin-catenin complex: protein interactions and their implications for cadherin function," (1996) <u>J. Cell. Biochem.</u> 61:514-523," (1996) <u>J. Cell. Biochem.</u> 61:514-523	
	C2	Adam, M.A. and A.D. Miller, "Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions," (1988) <u>J. Virol.</u> 62:3802-3806	
	C3	Adams et al., "Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation," (1997) <u>J. Clin. Invest.</u> 100:3149-3153	
	C4	Adams, J.C. et al., "The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development," Tucker (2000) <u>Dev. Dyn.</u> 218:280-299	
	C5	Altschul, S.F. et al., "Basic local alignment search tool," (1990) <u>J. Mol. Biol.</u> 215:403-410	
	C6	Anderson, N.L. and J. Seilhamer, "A comparison of selected mRNA and protein abundances in human liver," (1997) <u>Electrophoresis</u> 18:533-537	
	C7	Antinozzi, P.A. et al., "Metabolic engineering with recombinant adenoviruses," (1999) <u>Annu. Rev. Nutr.</u> 19:511-544	
	C8	Armentano, D. et al., "Effect of internal viral sequences on the utility of retroviral vectors," (1987) <u>J. Virol.</u> 61:1647-1650	
	C9	Arndt, G.M. et al., "A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells," (2000) <u>Nucleic Acids Res.</u> 28:E15	
	C10	Ashkenazi, A. and V.M. Divit, "Apoptosis control by death and decoy receptors," (1999) <u>Curr. Opin. Cell Biol.</u> 11:255-260	
	C11	Auwerx, J., "PPAR $\gamma$ , the ultimate thrifty gene," (1999) <u>Diabetologia</u> 42:1033-1049	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/524,355
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	3	of	22
		<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C12	Baltimore, D., "Intracellular Immunization," (1988) <u>Nature</u> 335:395-396	
	C13	Banerji, J. et al., "A gene pair from the human major histocompatibility complex encodes large praline-rich proteins with multiple repeated motifs and a single ubiquitin-like domain," (1990) <u>Proc. Natl. Acad. Sci. USA</u> 87:2374-2378	
	C14	Barroso et al., "Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension," (1998) <u>Nature</u> 402:880-883	
	C15	Bauer, G. et al., "Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized D34+cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes," (1997) <u>Blood</u> 89:2259-2267	
	C16	Bender, M.A. et al., "Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region," (1987) <u>J. Virol.</u> 61:1639-1646	
	C17	Bitter, G.A. et al., "Expression and secretion vectors for yeast," (1987) <u>Methods Enzymol.</u> 153:516-544	
	C18	Blaese, R.M. et al., "T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years," (1995) <u>Science</u> 270:475-480	
	C19	Blind, M. et al., "Cytoplasmic RNA modulators of an inside-out signal-transduction cascade," (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96:3606-3610	
	C20	Boado, R.J. et al., "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," (1998) <u>J. Pharm. Sci.</u> 87:1308-1315	
	C21	Bolton, A.E. and W.M. Hunter, "The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent," (1973) <u>Biochem. J.</u> 133:529-539	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	4	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C22	Bonyhadi, M.L., "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication," (1997) <u>J. Virol.</u> 71:4707-4716	
	C23	Bordignon, C. et al., "Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients," (1995) <u>Science</u> 270:470-475	
	C24	Boulay, J.-L. and H. Récipon, "Expression vectors and delivery systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:445-450	
	C25	Brenner, B. et al., "L-selectin regulates actinpolymerisation via activation of the small G-protein Rac2," (1997) <u>Biochem. Biophys. Res. Commun.</u> 231:802-807	
	C26	Brody, E.N. and L. Gold, "Aptamers as therapeutic and diagnosis agents," (2000) <u>J. Biotechnol.</u> 74:5-13	
	C27	Broglie, R. et al., "Light-regulated expression of a pea Ribulose-1,5-Bisphosphate Carboxylase small subunit gene in transformed plant cells," (1984) <u>Science</u> 224:838-843	
	C28	Brown, D.D. et al., "The thyroid hormone-induced tail resorption program during <i>Xenopus laevis</i> metamorphosis," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:1924-1929	
	C29	Brummelkamp, T.R. et al., "A system for stable expression of short interfering RNAs in mammalian cells," (2002) <u>Science</u> 296:550-553	
	C30	Brummendorf et al., "Structure/function relationships of axon-associated adhesion receptors of the immunoglobulin superfamily," (1996) <u>Curr. Opin. Neurobiol.</u> 6:584-593	
	C31	Buller, R.M. et al., "Decreased virulence of recombinant Vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype," (1985) <u>Nature</u> 317:813-815	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/524,355
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	5	of	22
		<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C32	Burge, C. and S. Karlin, "Finding the genes in genomic DNA," (1997) <u>J. Mol. Biol.</u> 268:78-94	
	C33	Burge, C. and S. Karlin, "Prediction of complete gene structures in human genomic DNA," (1998) <u>Curr. Opin. Struct. Biol.</u> 8:346-354	
	C34	Burton, D.R., "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:10134-10137	
	C35	Capecchi, M.R., "Altering the genome by homologous recombination," (1989) <u>Science</u> 244:1288-1292	
	C36	Caruthers, M.H. et al., "New chemical methods for synthesis in polynucleotides," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:215-223	
	C37	Cavazzana-Calvo, M. et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," (2000) <u>Science</u> 288:669-672	
	C38	Chang, C.-C. et al., "Evolution of a cytokine using DNA family shuffling," (1999) <u>Nat. Biotechnol.</u> 17:793-797	
	C39	Chen, L. et al., "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization," (1990) <u>Oncogene</u> 5:1391-1395	
	C40	Chicz, R.M. and F.Z. Regnier, "High-performance liquid chromatography: effective protein purification by various chromatographic modes," (1990) <u>Methods Enzymol.</u> 182:392-421	
	C41	Christians, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," (1999) <u>Nat. Biotechnol.</u> 17:259-264	
	C42	Chung, T.D., "Characterization of the role of IL-6 in the progression of prostate cancer," (1999) <u>Prostate</u> 15:199-207	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/524,355
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	6	<b>of</b>	22
		<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C43	Clarke, M.L. et al., "Comparative analysis of artificial antisense RNA regulation in fission yeast and human cells," (2000) <u>Biochem. Biophys. Res. Commun.</u> 268:8-13	
	C44	Colbere-Garapin, F. et al., "A new dominant hybrid selective marker for higher eukaryotic cells," (1981) <u>J. Mol. Biol.</u> 150:1-14	
	C45	Cole, S.P. et al., "Human monoclonal antibodies," (1984) <u>Mol. Cell Biol.</u> 62:109-120	
	C46	Colombatti, A. et al., "The superfamily of proteins with von Willebrand Factor type A-like domains: one theme common to components of extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms," (1991) <u>Blood</u> 77:2305-2315	
	C47	Coruzzi, G. et al., "Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of rebulose-1,5-bisphosphate carboxylase," (1984) <u>EMBO J.</u> 3:1671-1680	
	C48	Cote, R.J. et al., "Generation of human monoclonal antibodies reactive with cellular antigene," (1983) <u>Proc. Natl. Acad. Sci. USA</u> 80:2026-2030	
	C49	Cramer, A. et al., "Improved green fluorescent protein by molecular evolution using DNA shuffling," (1996) <u>Nat. Biotechnol.</u> 14:315-319	
	C50	Crystal, R.G. et al., "A Phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung," (1995) <u>Hum. Gene Therapy</u> 6:643-666	
	C51	Crystal, R.G. et al., "Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis," (1995) <u>Hum. Gene Therapy</u> 6:667-703	
	C52	Crystal, R.G., "Transfer of genes to humans: Early lessons and obstacles to success," (1995) <u>Science</u> 270:404-410	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	7	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C53	Csete, M.E. et al., "Efficient gene transfer to pancreatic islets mediated by adenoviral vectors," (1995) <u>Transplantation</u> 27:263-268	
	C54	Cunningham, B.C. and J.A. Wells, "Rational design of receptor-specific variants of human growth hormone," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:3407-3411	
	C55	Davis, C.G., "The many faces of epidermal growth factor repeats," (1990) <u>New Biol.</u> 5:410-419	
	C56	de la Fuente, M.A. et al., "CD84 leukocyte antigen is a new member of the Ig superfamily," (1997) <u>Blood</u> 90:2398-2405	
	C57	Deak, F. et al., "Primary structure and expression of Matrilin-2, the closest relative of cartilage matrix protein within the von Willebrand factor Type A-like module superfamily," (1997) <u>J. Biol. Chem.</u> 272:9268-9274	
	C58	Dix, K.J., et al., "Comparative Metabolism and Disposition of Gemfibrozil in Male and Female Sprague-Dawley Rats and Syrian golden Hamsters," (1999) <u>Drug Metab. Distrib.</u> 27:138-146	
	C59	Drickamer, K. et al., "Biology of animal lectins," (1993) <u>Annu. Rev. Cell Biol.</u> 9:237-264	
	C60	Dryga, S.A. et al., "Identification of mutations in a sindbis virus variant able to establish persistent infection in BHK cells: The importance of a mutation in the nsP2 gene," (1997) <u>Virology</u> 228:74-83	
	C61	Dull, T. et al., "A third-generation lentivirus vector with a conditional packaging system," (1998) <u>J. Virol.</u> 72:8463-8471	
	C62	Duplaa, C. et al., "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <u>Anal. Biochem.</u> 212:229-236	
	C63	Eddy, S.R., "Hidden markov models," (1996) <u>Curr. Opin. Struct. Biol.</u> 6:361-365	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/524,355
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	8	of	22
		<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C64	Elbashir, S.M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," (2001) <u>Nature</u> 411:494-498	
	C65	Engelhard, E.K. et al., "The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus," (1994) <u>Proc. Natl. Acad. Sci. USA</u> 91:3224-3227	
	C66	Faissner, A., "The tenascin gene family in axon growth and guidance," (1997) <u>Cell Tissue Res.</u> 290:331-341	
	C67	Fawcett, J. et al., "Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes," (1992) <u>Nature</u> 360:481-484	
	C68	Fields, S. and O. Song, "A novel genetic system to detect protein-protein interactions," (1989) <u>Nature</u> 340:245-246	
	C69	Fire, A. et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," (1998) <u>Nature</u> 391:806-811	
	C70	Frick, M.H., et al., "Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia," (1987) <u>New Engl. J. Med.</u> ; 317:1237-1245	
	C71	Frisch, S.M. et al., "Integrins and anoikis," (1997) <u>Curr. Opin. Cell Biol.</u> 9:701-706	
	C72	Funatsu, N. et al., "Characterization of a Novel Rat Brain Glycosylphosphatidylinositol-anchored Protein (Kilon), a Member of the IgLON Cell Adhesion Molecule Family," (1999) <u>J. Biol. Chem.</u> 274:8224-8230	
	C73	Garoff, H. et al., "Recent advances in gene expression using alphavirus vectors," (1998) <u>Curr. Opin. Biotechnol.</u> 9:464-469	
	C74	Gary, S.C. et al., "BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility," (1998) <u>Curr. Opin. Neurobiol.</u> 8:576-581	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	9	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C75	Gatti, R.A. et al., "Localization of an ataxia-telangiectasia gene to chromosome," (1988) <u>Nature</u> 336:577-580	
	C76	Goins, W.F. et al., "Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity," (1999; <u>J. Virol.</u> 73:519-532	
	C77	Gold, L.I. (1999) <u>Crit. Rev. Oncol.</u> 10:303-360 (waiting from SD library)	
	C78	Goldman, C.K. et al., "In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer," (1997) <u>Nat. Biotechnol.</u> 15:462-466	
	C79	Gossen, M. and H. Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89:5547-5551	
	C80	Gossen, M. et al., "Transcriptional activation by tetracyclines in mammalian cells," (1995) <u>Science</u> 268:1766-1769	
	C81	Graham, F.L. and A.J. Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA," (1973) <u>Virology</u> 52:456-467	
	C82	Gregoire et al., "Understanding adipocyte differentiation," (1998) <u>Physiol. Reviews</u> 78:783-809	
	C83	Gu, K. et al., "Human dentin phosphophoryn nucleotide and amino acid sequence," (1998) <u>Eur. J. Oral Sci.</u> 106:1043-1047	
	C84	Gura, T., "A silence that speaks volumes," (2000) <u>Nature</u> 404:804-808	
	C85	Hadari, Y.R. et al., "Galectin-8; A new rat lectin, related to galectin-4," (1995) <u>J. Biol. Chem.</u> 270:3447-3453	
	C86	Haft, D.H. et al., "TIGRFAMs: a protein family resource for the functional identification of proteins," (2001) <u>Nucleic Acids Res.</u> 29:41-43	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>			
		<b>Application Number</b>	10/524,355		
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005		
		<b>First Named Inventor</b>	Vicki S. Elliott		
		<b>Group Art Unit</b>	Unassigned		
		<b>Examiner Name</b>	Unassigned		
<b>Sheet</b>	10	of	22	<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C87	Hanks, S.K. et al., "Signaling through focal adhesion kinase," (1997) <u>BioEssays</u> 19:137-145	
	C88	Harrington, J.J. et al., "Formation of de novo centromere and construction of first-generation human artificial microchromosomes," (1997) <u>Nat. Genet.</u> 15:345-355	
	C89	Harrington, M.G., "Elution of protein from gels," (1990) <u>Methods Enzymol.</u> 182:488-495	
	C90	Hartman, S.C. and R.C. Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <u>Proc. Natl. Acad. Sci. USA</u> 85:8047-8051	
	C91	Heller, R.A. et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," (1997) <u>Proc. Natl. Acad. Sci. USA</u> 94:2150-2155	
	C92	Hidari, K. I. et al., "Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils," (1997) <u>J. Biol. Chem.</u> 272:28750-28756	
	C93	Higgins, D.G. et al., "CLUSTAL V: Improved software for multiple sequence alignment," (1992) <u>CABIOS</u> 8:189-191	
	C94	Higgins, D.G. et al., "Fast and sensitive multiple sequence alignments on a microcomputer," (1989) <u>CABIOS</u> 5:151-153	
	C95	Horn, T. et al., "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for gastric inhibitory polypeptide (GIP)," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:225-232	
	C96	Howard, A.D. et al., "Orphan G-protein-coupled receptors and natural ligand discovery," (2001) <u>Trends Pharmacol. Sci.</u> 22:132-140	
	C97	Huse, W.D. et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in Phage Lambda," (1989) <u>Science</u> 246:1275-1281	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	11	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C98	Ivics, Z., "Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells," (1997) <u>Cell</u> 91:501-510	
	C99	Khazaie, K. et al., "EGF receptor in neoplasia and metastasis," (1993) <u>Cancer and Metastasis Rev.</u> 12:255-274	
	C100	Kimmel, A.R., "Identification and characterization of specific clones: Strategy for confirming the validity of presumptive clones," (1987) <u>Methods Enzymol.</u> 152:507-511	
	C101	Kobe, B. et al., "Proteins with leucine-rich repeats," (1995) <u>Curr. Opin. Struct. Biol.</u> 5:409-416	
	C102	Kohda, D. et al., "Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration," (1996) <u>Cell</u> 86:767-775	
	C103	Kohler, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) <u>Nature</u> 256:495-497	
	C104	Kozbor, D. et al., "Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas," (1985) <u>J. Immunol. Methods</u> 81:31-42	
	C105	Kulkarni, N.H. et al., "Characterization and differential expression of a human gene family of olfactomedin-related proteins," (2000) <u>Genet. Res.</u> 76:41-50	
	C106	Kwok, P.-Y. and Z. Gu, "Single nucleotide polymorphism libraries: why and how are we building them?," (1999) <u>Mol. Med. Today</u> 5:538-543	
	C107	Lagerstrom, M. et al., "Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA," (1991) <u>PCR Methods Applic.</u> 1:111-119	
	C108	Lander, E.S. and D. Botstein, "Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms," (1986) <u>Proc. Natl. Acad. Sci. USA</u> 83:7353-7357	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/524,355
		Filing Date	07/12/2005
		First Named Inventor	Vicki S. Elliott
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	12	of	22
		Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C109	Lasky, L.A., "Lectin cell adhesion molecules (LEC-CAMs): a new family of cell adhesion proteins involved with inflammation," (1991) <u>J. Cell. Biochem.</u> 45:139-146	
	C110	Lee, J.-O. et al., "Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18)," (1995) <u>Cell</u> 80:631-638	
	C111	Lee, S.W. et al., "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment," (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89:2504-2508	
	C112	Letunic, I. et al., "Recent improvements to the SMART domain-based sequence annotation resource," (2002) <u>Nucleic Acids Res.</u> 30:242-244	
	C113	Li, W. et al., "Reduced hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta," (2001) <u>Matrix Biol.</u> 19(8):755-60	
	C114	Lin, J. et al., "The Phosphatidylinositol 3'-kinase Pathway Is a Dominant Growth Factor-activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells," (1999) <u>Cancer Res.</u> 59:2891-2897	
	C115	Liu, X. et al., "Herpes simplex virus mediated gene transfer to primate ocular tissues," (1999) <u>Exp. Eye Res.</u> 169:385-395	
	C116	Logan, J. and T. Shenk, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:3655-3659	
	C117	Lois, C. et al., "Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors," (2002) <u>Science</u> 295:868-872	
	C118	Lowman, H.B. et al., "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen," (1991) <u>J. Biol. Chem.</u> 266:10982-10988	
	C119	Lowy, I. et al., "Isolation of transforming DNA: cloning the hamster apt gene," (1980) <u>Cell</u> 22:817-823	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>			
		<b>Application Number</b>	10/524,355		
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005		
		<b>First Named Inventor</b>	Vicki S. Elliott		
		<b>Group Art Unit</b>	Unassigned		
		<b>Examiner Name</b>	Unassigned		
<b>Sheet</b>	13	of	22	<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C120	Lueking, A. et al., "Protein microarrays for gene expression and antibody screening," (1999) <u>Anal. Biochem.</u> 270:103-111	
	C121	Manda et al., "Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display," (1999) <u>Genomics</u> 51:5-14	
	C122	Mantovani, A. et al., "Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines," (2001) <u>Trends Immunol.</u> 22:328-336	
	C123	Marshall, A. and J. Hodgson, "DNA Chips: an array of possibilities," (1998) <u>Nat. Biotechnol.</u> 16:27-31	
	C124	Marth, J.D., "Recent advances in gene mutagenesis by site-directed recombination," (1996) <u>Clin. Invest.</u> 97:1999-2002	
	C125	Matthews, D.J. and J.A. Wells, "Engineering an interfacial zinc site to increase hormone-receptor affinity," (1994) <u>Chem. Biol.</u> 1:25-30	
	C126	Maurer, P. et al., "Extracellular calcium-binding proteins," (1996) <u>Curr. Opin. Cell Biol.</u> 8:609-617	
	C127	McGregor, D.P. et al., "Spontaneous assembly of bivalent single chain antibody fragments in ESCHERICHIA COLI," (1994) <u>Mol. Immunol.</u> 31:219-226	
	C128	Melby, P.C. et al., "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) <u>J. Immunol. Methods</u> 159:235-244	
	C129	Mendoza, L.G. et al., "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)," (1999) <u>Biotechniques</u> 27:778-788	
	C130	Mickelson et al., "Differential expression and release of CD54 induced by cytokines," (1995) <u>Hepatology</u> 22:866-875	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	14	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C131	Midwood, K.S., "Elastic Fibers: Building Bridges Between Cells and Their Matrix [Dispatch]," (2002) <u>Current Biology</u> 12:R279-R281	
	C132	Miller, A.D., "Progress toward human gene therapy," (1990) <u>Blood</u> 76:271-278	
	C133	Miyamoto, S. et al., "Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors," (1996) <u>J. Cell Biol.</u> 135:1633-1642	
	C134	Miyata, S. et al., "Expression of the IgLON cell adhesion molecules kilon and OBCAM in hypothalamic magnocellular neurons," (2000) <u>J. Comp. Neurol.</u> 424:74-85	
	C135	Montgomery, A.M. et al., "Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3," (1996) <u>J. Cell Biol.</u> 132:475-485	
	C136	Morgan, R.A. and W.F. Anderson, "Human gene therapy," (1993) <u>Annu. Rev. Biochem.</u> 62:191-217	
	C137	Morris, M.C. et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," (1997) <u>Nucleic Acids Res.</u> 25:2730-2736	
	C138	Morrison, S.L. et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855	
	C139	Muyldermans, S., "Single domain camel antibodies: current status," (2001) <u>J. Biotechnol.</u> 74:277-302	
	C140	Nagasawa, A. et al., "Human and mouse ISLR (immunoglobulin superfamily containing leucine-rich repeat) genes: genomic structure and tissue expression," (1999) <u>Genomics</u> 61:37-43	
	C141	Nagendra et al., "CD18 integrin and CD54-dependent neutrophil adhesion to cytokine-stimulated human hepatocytes," (1997) <u>Am. J. Physiol.</u> 272:G408-G416	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	15	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C142	Neuberger, M.S. et al., "Recombinant antibodies possessing novel effector functions" (1984) <u>Nature</u> 312:604-608	
	C143	Neumann, E. et al., "Gene transfer into mouse lyoma cells by electroporation in high electric fields," (1982) <u>EMBO J.</u> 1:841-845	
	C144	Nowotny, P. et al., "SNP analysis to dissect human traits," (2001) <u>Curr. Opin. Neurobiol.</u> 11:637-641	
	C145	Nuwaysir, E.F. et al., "Microarrays and toxicology: the advent of toxicogenomics," (1999) <u>Mol. Carcinog.</u> 24:153-159	
	C146	Oba, K. et al., "Two putative tumor suppressor genes on chromosome arem 8p may ply different roles in prostate cancer," (2001) <u>Cancer Genet. Cytogenet.</u> 124: 20-26	
	C147	Oleszewski, M. et al., "Implications for L1-L1 homophilic binding," (2000) <u>J. Biol. Chem.</u> 275:34478-34485	
	C148	Orlandi, R. et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <u>Proc. Natl. Acad. Sci. USA</u> 86:3833-3837	
	C149	Paddison, P.J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," (2002) <u>Genes Dev.</u> 16:948-958	
	C150	Paietta, E. et al., "Hodgkin's cell lectin, a lymphocyte adhesion molecule and mitogen," (1989) <u>J. Immunol.</u> 143:2850-2857	
	C151	Parker, J.D. et al., "Targeted gene walking polymerase chain reaction," (1991) <u>Nucleic Acids Res.</u> 19:3055-3060	
	C152	Perou, C.M. et al., "Molecular portraits of human breast tumours," (2000) <u>Nature</u> 406:747-752	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		Application Number	10/524,355
		Filing Date	07/12/2005
		First Named Inventor	Vicki S. Elliott
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	071949-9301

(use as many sheets as necessary)

Sheet	16	of	22
-------	----	----	----

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C153	Petersen et al., "Gene therapy expression profiling of advanced lung cancer," (2000) <u>Int J. Cancer</u> , 86:512-517	
	C154	Poeschla, E. et al., "Development of HIV vectors for anti-HIV gene therapy," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:11395-11399	
	C155	Ponting, C.P. et al., "A latrophilin/CL-1-like GPS domain in polycystin-1," (1999) <u>Curr. Biol.</u> 9:R585-R588	
	C156	Putz, T. et al., "Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines," (1999) <u>Cancer Res.</u> 59:227-233	
	C157	Ranga, U. et al., "Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene," (1997) <u>J. Virol.</u> 71:7020-7029	
	C158	Ranga, U. et al., "Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:1201-1206	
	C159	Rao, V.B., "Direct sequencing of polymerase chain reaction-amplified DNA," (1994) <u>Anal. Biochem.</u> 216:1-14	
	C160	Raper, J.A., "Semaphorins and their receptors in vertebrates and invertebrates," (2000) <u>Curr. Opin. Neurobiol.</u> 10:88-94	
	C161	Reznicek, G. A. et al., "Linking integrin $\alpha_6\beta_4$ -based cell adhesion to the intermediate filament cytoskeleton: direct interaction between the $\beta_4$ subunit and plectin at multiple molecular sites," (1998) <u>J. Cell Biol.</u> 141:209-225	
	C162	Rhodes, C.A., "Transformation of maize by electroporation of embryos," (1995) <u>Methods Mol. Biol.</u> 55:121-131	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	17	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C163	Riviere, I. et al., "Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells," (1995) <u>Proc. Natl. Acad. Sci. USA</u> 92:6733-6737	
	C164	Roberge, J.Y. et al., "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) <u>Science</u> 269:202-204	
	C165	Rossi, F.M.V. and H.M. Blau, "Recent advances in inducible gene expression systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:451-456	
	C166	Rossi, J.J., "Therapeutic antisense and ribozymes," (1995) <u>Br. Med. Bull.</u> 51:217-225	
	C167	Sager, R. et al., "Maspin: A tumor suppressing serpin," (1996) <u>Curr. Top. Microbiol. Immunol.</u> 213:51-64	
	C168	Sandig, V. et al., "Gene transfer into hepatocytes and human liver tissue by baculovirus vectors," (1996) <u>Hum. Gene Ther.</u> 7:1937-1945	
	C169	Sarkar, G., "Restriction-site PCR: a direct method of unknown sequence retrieval adjacent to a known locus by using universal primers," (1993) <u>PCR Methods Applic.</u> 2:318-322	
	C170	Scanlon, K.J. et al., "Oligonucleotide-mediated modulation of mammalian gene expression," (1995) <u>FASEB J.</u> 9:1288-1296	
	C171	Scharf, D. et al., "Heat stress promoters and transcription factors," (1994) <u>Results Probl. Cell Differ.</u> 20:125-162	
	C172	Schena, M. et al., "Parallel human genome analysis: microarray-based expression monitoring of 1000 genes," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:10614-10619	
	C173	Schena, M. et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," (1995) <u>Science</u> 270:467-470	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	18	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C174	Schultz, J. et al., "SAM as a protein interaction domain involved in developmental regulation," (1997) <u>Protein Sci.</u> 6:249-253	
	C175	Schultz, J. et al., "SMART, a simple modular architecture research tool: Identification of signaling domains," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:5857-5864	
	C176	Schwarze, S.R. et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse," (1999) <u>Science</u> 285:1569-1572	
	C177	Scorer, C.A. et al., "Rapid selection using G418 of high copy number transformants of Pichia Pastoris for high-level foreign gene expression," (1994) <u>Bio/Technology</u> 12:181-184	
	C178	Shalon, D. et al., "A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization," (1996) <u>Genome Res.</u> 6:639-645	
	C179	Skerra, A., "Anticalins: A new class of engineered ligand-binding proteins with antibody-like properties," (2001) <u>J. Biotechnol.</u> 74:257-275	
	C180	Slater, J.E., "Environmental and occupational disorders," et al. (1998) <u>J. Allergy Clin. Immunol.</u> 102:469-475	
	C181	Steiner, S. and N.L. Anderson, "Expression profiling in toxicology—potentials and limitations," (2000) <u>Toxicol. Lett.</u> 112-113:467-471	
	C182	Su, L., "Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro," (1997) <u>Blood</u> 89:2283-2290	
	C183	Su, Z.-Z. et al., "Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:7252-7257	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/524,355
(use as many sheets as necessary)		<b>Filing Date</b>	07/12/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
<b>Sheet</b>	19	of	22
		<b>Attorney Docket Number</b>	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C184	Suzuki et al., "Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones," (2000) <u>Jpn. J. Pharmacol.</u> 84:113-123	
	C185	Suzuki, S.T., "Protocadherins and diversity of the cadherin superfamily," (1996) <u>J. Cell Sci.</u> 109:2609-2611	
	C186	Takamatsu, N., "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TRV-RNA," (1987) <u>EMBO J.</u> 6:307-311	
	C187	Takeda, S., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," et al. (1985) <u>Nature</u> 314:452-454	
	C188	Taylor, "Using genetic variation to study human disease," (1999) <u>Cell</u> 97:9-12	
	C189	Taylor, J.G. et al., "Deconstructing type 2 diabetes," (2001) <u>Trends Mol. Med.</u> 7:507-512	
	C190	Taylor, P.C. et al., "Immunotherapy for rheumatoid arthritis," (2001) <u>Curr. Opin. Immunol.</u> 13:611-616	
	C191	Theopold, U. et al., "Helix pomatia lectin, an inducer of Drosophila immune response, binds to Hemomucin, a novel surface mucin," (1996) <u>J. Biol. Chem.</u> 271:12708-12715	
	C192	Thomas, B.F., et al., "Isolation and identification of novel metabolites of gemfibrozil in rat urine," (1999) <u>Drug Metab. Distrib.</u> 27:147-157	
	C193	Thomson, J.A. et al., "Embryonic stem cell lines derived from human blastocysts," (1998) <u>Science</u> 282:1145-1147	
	C194	Toribara, N.W. et al., "Human gastric mucin. Identification of a unique species by expression cloning," (1993) <u>J. Biol. Chem.</u> 268:5879-5885	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/524,355
				Filing Date	07/12/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	20	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C195	Toribara, N.W. et al., "The carboxyl-terminal sequence of the human secretory Mucin, MUC6. Analysis of the primary amino acid sequence," (1997) <u>J. Biol. Chem.</u> 272:16398-16403	
	C196	Tran, H. et al., "The self-association and fibronectin-binding sites of fibulin-1 map to calcium-binding epidermal growth factor-like domains," (1997) <u>J. Biol. Chem.</u> 272:22600-22606	
	C197	Trask, B.J., "Fluorescence in situ hybridization," (1991) <u>Trends Genet.</u> 7:149-154	
	C198	Triglia, T. et al., "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," (1988) <u>Nucleic Acids Res.</u> 16:8186	
	C199	Uckert, W. and W. Walther (1994) <u>Pharmacol. Ther.</u> 63:323-347	
	C200	Ulrix, W. et al., "The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells," (1999) <u>FEBS Lett</u> 455:23-26	
	C201	Uyemura, K. et al., "Cell-adhesion proteins of the immunoglobulin superfamily in the nervous system," (1996) <u>Essays Biochem.</u> 31:37-48	
	C202	Van Heeke, G. and S.M. Schuster, "Expression of human synthetase in Escherichia coli," (1989) <u>J. Biol. Chem.</u> 264:5503-5509	
	C203	Verma, I.M. and N. Somia, "Gene therapy - promises, problems and prospects," (1997) <u>Nature</u> 18:389:239-242	
	C204	Wagner, K.U. et al., "Cre-mediated gene deletion in the mammary gland," (1997) <u>Nucleic Acids Res.</u> 25:4323-4330	
	C205	Wahl, G.M. and S.L. Berger, "Molecular hybridization of immobilized nucleic acids: theoretical concepts and practical considerations," (1987) <u>Methods Enzymol.</u> 152:399-407	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/524,355		
		Filing Date	07/12/2005		
		First Named Inventor	Vicki S. Elliott		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	21	of	22	Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C206	Wang et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," (2000) <u>Oncogene</u> 19:1519-1528	
	C207	Way et al., "Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor $\gamma$ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues," (2001) <u>Endocrinology</u> 142:1269-1277	
	C208	Weiss, G.A. and H.B. Lowman, "Anticalins versus antibodies: made-to-order binding proteins for small molecules," (2000) <u>Chem. Biol.</u> 7:R177-R184	
	C209	Wigler, M. et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) <u>Cell</u> 11:223-232	
	C210	Wigler, M. et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <u>Proc. Natl. Acad. Sci. USA</u> 77:3567-3570	
	C211	Winter, G. et al., "Man-made antibodies," (1991) <u>Nature</u> 349:293-299	
	C212	Winter, J. et al., "The expression of heat shock protein and cognate genes during plant development," (1991) <u>Results Probl. Cell Differ.</u> 17:85-105	
	C213	Wise, A. et al., "Target validation of G-protein coupled receptors," (2002) <u>Drug Discovery Today</u> 7:235-246	
	C214	Wistuba, I.I. et al., "Comparison of features of human breast cancer cell lines and their corresponding tumors," (1998) <u>Clin. Cancer Res.</u> 4:2931-2938	
	C215	Xu, H. et al., "Viral transduction of trkA into cultured nodose and spinal motor neurons conveys NGF responsiveness," (1994) <u>Dev. Biol.</u> 163:152-161	
	C216	Yang, Y. et al., "The structural basis of ankyrin-like repeat function as revealed by the solution structure of myotrophin," (1998) <u>Structure</u> 6:619-626	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/524,355
		Filing Date	07/12/2005
		First Named Inventor	Vicki S. Elliott
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	22	of	22
		Attorney Docket Number	071949-9301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C217	Yao, I. et al., "Synamon, a Novel Neuronal Protein Interacting with Synapse-associated Protein 90/Postsynaptic Density-95-associated Protein," (1999) <u>J. Biol. Chem.</u> 274: 27463-27466	
	C218	Yu, M. et al., "A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1," (1993) <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344	
	C219	Zabner, J. et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in masal epithelia of patients with cystic fibrosis," (1993) <u>Cell</u> 75:207-216	
	C220	Zhou, Z. et al., "Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors," (1998) <u>Int. J. Cancer</u> 78:95-99	
	C221	Zitzer, H. et al., "Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain," (1999) <u>J. Biol. Chem.</u> 274:32997-33001	
	C222	Zufferey, R. et al., "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery," (1998) <u>J. Virol.</u> 72:9873-9880	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.